PharmaKure and Universiti Teknologi MARA (UiTM) partner for Alzheimer’s diagnosis research
Betsy Goodfellow | December 13, 2023 | News story | Medical Communications | Alzheimer's disease, Neurology, PharmaKure, UiTM
PharmaKure and the faculty of pharmacy at the University Teknologi MARA (UiTM), Malaysia, have announced a research collaboration focusing on advancing research initiatives surrounding the use of machine learning (ML) tools in order to predict Alzheimer’s disease (AD) using blood testing.
Dr Farid Khan, chief executive officer of PharmaKure, commented: “The UK has an ageing population, where one in 14 people over the age of 65 have AD. There is an urgent need to not only identify people who will develop this devasting disease but also develop treatments. This agreement marks a significant milestone in establishing a research collaboration with UiTM, a leading academic institute, allowing us to partner with leading experts and enhance our in-house expertise in the analysis of molecular signatures of disease biomarkers associated with Alzheimer’s. We recently announced ALZmetrixTM, our whole blood test, together with our machine tools can predict which biomarkers are most useful in detecting people at high risk of developing Alzheimer’s diseases.”
Dr Abu Bakar Abdul Majeed, dean of the faculty of pharmacy at UiTM, added: “Malaysia is expected to be an ageing nation by 2030, with almost half a million dementia patients predicted in 2050. That’s why this research partnership is important; we want to drive innovation and have societal impact both here and in the rest of the world. Alzheimer’s is a complex disease, by combining UiTM’s and PharmaKure’s biomarker, clinical and imaging data together with ML algorithms we will gain better understanding of how this disease develops and ultimately find ways to treat it.”
Betsy Goodfellow
Related Content
Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …
Roche receives CE Mark for blood test to help rule out Alzheimer’s
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …
Sanofi to acquire Vigil Neuroscience, adding Alzheimer’s disease candidate to early-stage pipeline
Sanofi has announced an agreement to acquire Vigil Neuroscience, a biotech company focused on therapies …
